Genmab A/S (NASDAQ:GMAB) Earns Buy Rating from Analysts at Redburn Atlantic

Redburn Atlantic started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Tuesday, Marketbeat reports. The brokerage issued a buy rating on the stock.

Several other equities research analysts have also recently weighed in on GMAB. Truist Financial dropped their price objective on Genmab A/S from $53.00 to $50.00 and set a buy rating for the company in a report on Monday, September 9th. Morgan Stanley reaffirmed an equal weight rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a buy rating in a research report on Thursday, June 27th. HC Wainwright reissued a buy rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of Moderate Buy and an average price target of $45.20.

Genmab A/S Stock Performance

Genmab A/S stock opened at $23.71 on Tuesday. Genmab A/S has a fifty-two week low of $23.24 and a fifty-two week high of $35.88. The stock has a market cap of $15.69 billion, a P/E ratio of 19.60, a PEG ratio of 0.71 and a beta of 0.98. The firm’s fifty day moving average price is $26.26 and its 200-day moving average price is $27.42.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. Sell-side analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC increased its stake in Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after purchasing an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Genmab A/S during the 1st quarter valued at about $43,000. Barometer Capital Management Inc. purchased a new position in Genmab A/S in the fourth quarter worth about $121,000. Finally, Headlands Technologies LLC lifted its stake in shares of Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after buying an additional 4,853 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.